[go: up one dir, main page]

ZA201001066B - Novel forms of CDDO methyl ester - Google Patents

Novel forms of CDDO methyl ester

Info

Publication number
ZA201001066B
ZA201001066B ZA201001066A ZA201001066A ZA201001066B ZA 201001066 B ZA201001066 B ZA 201001066B ZA 201001066 A ZA201001066 A ZA 201001066A ZA 201001066 A ZA201001066 A ZA 201001066A ZA 201001066 B ZA201001066 B ZA 201001066B
Authority
ZA
South Africa
Prior art keywords
methyl ester
novel forms
cddo methyl
cddo
novel
Prior art date
Application number
ZA201001066A
Other languages
English (en)
Inventor
John Walling
Stephan D Parent
David T Jonaitis
Robert M Kral
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of ZA201001066B publication Critical patent/ZA201001066B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Glass Compositions (AREA)
ZA201001066A 2007-08-15 2010-02-12 Novel forms of CDDO methyl ester ZA201001066B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95593907P 2007-08-15 2007-08-15

Publications (1)

Publication Number Publication Date
ZA201001066B true ZA201001066B (en) 2010-10-27

Family

ID=40351005

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201001066A ZA201001066B (en) 2007-08-15 2010-02-12 Novel forms of CDDO methyl ester

Country Status (28)

Country Link
US (3) US8088824B2 (fr)
EP (2) EP2450057B1 (fr)
JP (4) JP5005812B2 (fr)
KR (2) KR101481764B1 (fr)
CN (2) CN101820758B (fr)
AR (2) AR073155A1 (fr)
AT (1) ATE549035T1 (fr)
AU (1) AU2008287388B2 (fr)
BR (1) BRPI0815540A8 (fr)
CA (2) CA2871864C (fr)
CL (1) CL2008002417A1 (fr)
CY (2) CY1112864T1 (fr)
DK (2) DK2187741T3 (fr)
EA (2) EA018704B1 (fr)
ES (2) ES2382571T3 (fr)
HR (2) HRP20120350T1 (fr)
HU (1) HUE031866T2 (fr)
IL (2) IL203824A (fr)
LT (1) LT2450057T (fr)
MX (1) MX2010001628A (fr)
NZ (1) NZ583269A (fr)
PL (2) PL2187741T3 (fr)
PT (2) PT2450057T (fr)
SG (2) SG177905A1 (fr)
SI (2) SI2187741T1 (fr)
TW (2) TWI486357B (fr)
WO (1) WO2009023232A1 (fr)
ZA (1) ZA201001066B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
AU2003235676A1 (en) 2002-01-15 2003-07-30 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2008064132A2 (fr) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Triterpénoïdes synthétiques et bis-énones tricycliques pour une utilisation dans la stimulation de croissance osseuse et cartilagineuse
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
CA2670099A1 (fr) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthese et activites biologiques de nouveaux composes tricycliques-bis-enones (tbe)
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
LT2252283T (lt) * 2008-01-11 2019-03-25 Reata Pharmaceuticals, Inc. Sintetiniai triterpenoidai ir jų panaudojimo būdai gydant ligą
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
LT2271658T (lt) 2008-04-18 2017-02-27 Reata Pharmaceuticals, Inc. Antioksidantai uždegimo moduliatoriai:oleanolio rūgšties c-17 patvirtinti dariniai
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター:c−17においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146216A2 (fr) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Modulateurs d’inflammation antioxydant : nouveaux dérivés d’acide oléanolique
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
US8314137B2 (en) 2008-07-22 2012-11-20 Trustess Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8747901B2 (en) * 2009-02-13 2014-06-10 Reata Pharmaceuticals, Inc. Delayed release, oral dosage compositions that contain amorphous CDDO-Me
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
CN102762101B (zh) 2010-02-18 2014-09-17 高点制药有限责任公司 取代的稠合咪唑衍生物、药物组合物及其使用方法
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
HRP20171859T1 (hr) 2010-12-17 2018-01-26 Reata Pharmaceuticals, Inc. Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
SMT201900433T1 (it) 2011-03-11 2019-09-09 Reata Pharmaceuticals Inc Derivati di c4-monometil triterpenoidi e metodi del loro uso
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
LT2841445T (lt) 2012-04-27 2017-09-11 Reata Pharmaceuticals, Inc. Bardoksolonmetilo 2,2-difluorpropionamido dariniai, polimorfinės formos ir jų panaudojimo būdai
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (fr) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. Dérivés c13-hydroxy de l'acide oléanolique et leurs procédés d'utilisation
MY180903A (en) 2012-09-10 2020-12-11 Reata Pharmaceuticals Inc C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
CN104936972A (zh) * 2012-09-10 2015-09-23 艾伯维公司 具有抗炎活性的甘草次酸衍生物
JP5972986B2 (ja) 2012-09-28 2016-08-17 アプライド ファーマシューティカル サイエンス インコーポレイテッド Cddoエチルエステルの多形体及びその用途
CN102875634B (zh) * 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) * 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
US9796752B2 (en) 2013-03-19 2017-10-24 Daiichi Sankyo Company, Limited Terpenoid derivatives
UY39092A (es) 2013-04-24 2021-03-26 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
WO2015027206A1 (fr) * 2013-08-23 2015-02-26 Reata Pharmaceuticals, Inc. Procédés de traitement et de prévention d'un dysfonctionnement endothélial au moyen de bardoxolone méthyle ou d'analogues de celui-ci
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US9896475B2 (en) 2014-08-26 2018-02-20 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
EP3192875B1 (fr) 2014-09-10 2019-12-18 Daiichi Sankyo Company, Limited Composition pharmaceutique à libération prolongée destinée au traitement et à la prévention de maladies ophtalmiques
WO2016089648A1 (fr) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant
US11591302B2 (en) 2014-12-19 2023-02-28 Geistlich Pharm A Ag Processes for preparing oxathiazin-like compounds
WO2016098054A1 (fr) 2014-12-19 2016-06-23 Geistlich Pharma Ag Procédés de préparation de composés de type oxathiazine
CN107428698B (zh) 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
PL3317281T3 (pl) * 2015-07-02 2020-11-02 Acerta Pharma B.V. Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
NZ741082A (en) 2015-09-23 2023-06-30 Reata Pharmaceuticals Inc C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
NZ753546A (en) * 2016-11-08 2022-10-28 Reata Pharmaceuticals Holdings Llc Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
EP3652193A1 (fr) 2017-07-13 2020-05-20 Pliva Hrvatska D.O.O. Nouvelles formes polymorphes cristallines du bardoxolone méthyle
JP7244536B2 (ja) 2018-04-06 2023-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ メタクリル酸メチル-メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
MX2020013692A (es) 2018-06-15 2021-02-26 Reata Pharmaceuticals Inc Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
WO2019246461A1 (fr) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Agonistes inverses dépendant de la cystéine de récepteurs nucléaires ror-gamma/ror-gamma-t et procédés de traitement de maladies ou de troubles associés
JPWO2020111089A1 (ja) 2018-11-27 2021-10-14 協和キリン株式会社 医薬組成物
CA3249188A1 (fr) 2019-07-19 2025-06-05 Reata Pharmaceuticals, Inc. Triterpénoïdes synthétiques hétéroaromatiques à substitution polaire c17 et leurs méthodes d’utilisation
CA3177913A1 (fr) 2020-05-09 2021-11-18 Deborah FERGUSON Procedes de traitement de la covid-19 a l'aide de methyle de barbarrolone ou d'analogues de celui-ci
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07121911B2 (ja) * 1986-03-26 1995-12-25 クミアイ化学工業株式会社 4(1h)−ピリジノン誘導体および農園芸用殺菌剤
JPH01273020A (ja) * 1988-04-26 1989-10-31 Toray Ind Inc 有機非線形光学材料
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
JP2876144B2 (ja) * 1990-03-23 1999-03-31 東洋フアルマー株式会社 3―フェニルクマリン―7―イルオキシ酢酸誘導体とその製法及び用途
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2430454A1 (fr) * 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Composes cddo et polytherapies associees
CA2485565A1 (fr) * 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibiteurs et procedes d'utilisation de ceux-ci
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
WO2005057275A1 (fr) 2003-12-08 2005-06-23 Sony Corporation Afficheur a cristaux liquides et procede de reglage de retroeclairage
US20060167097A1 (en) * 2004-04-16 2006-07-27 Cheppail Ramachandran Compositions and uses of Amooranin compounds
EP1904480A2 (fr) * 2005-05-23 2008-04-02 Novartis Pharma AG Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
AU2006325586B2 (en) 2005-12-12 2013-01-31 Mosamedix B.V. Annexin derivatives suitable for pretargeting in therapy and diagnosis
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester

Also Published As

Publication number Publication date
US8088824B2 (en) 2012-01-03
AU2008287388A1 (en) 2009-02-19
JP2018009001A (ja) 2018-01-18
EA023550B1 (ru) 2016-06-30
EA018704B1 (ru) 2013-10-30
CN103254267A (zh) 2013-08-21
US20120071684A1 (en) 2012-03-22
PL2450057T3 (pl) 2017-02-28
SI2187741T1 (sl) 2012-07-31
IL251419A0 (en) 2017-05-29
ES2602978T3 (es) 2017-02-23
PT2187741E (pt) 2012-06-21
PT2450057T (pt) 2016-12-15
WO2009023232A1 (fr) 2009-02-19
EA201370109A1 (ru) 2014-01-30
TW201402597A (zh) 2014-01-16
ES2382571T3 (es) 2012-06-11
CY1112864T1 (el) 2016-04-13
CA2871864A1 (fr) 2009-02-19
TW200916476A (en) 2009-04-16
KR101544766B1 (ko) 2015-08-17
HUE031866T2 (en) 2017-08-28
JP5005812B2 (ja) 2012-08-22
SG177905A1 (en) 2012-02-28
BRPI0815540A2 (pt) 2014-09-30
AR073155A1 (es) 2010-10-20
CN101820758A (zh) 2010-09-01
EP2187741A1 (fr) 2010-05-26
JP2012188438A (ja) 2012-10-04
JP2015164939A (ja) 2015-09-17
IL203824A (en) 2017-04-30
KR20140024063A (ko) 2014-02-27
CA2696330C (fr) 2015-03-24
BRPI0815540A8 (pt) 2023-04-11
MX2010001628A (es) 2010-06-02
LT2450057T (lt) 2016-12-27
PL2187741T3 (pl) 2012-08-31
CA2696330A1 (fr) 2009-02-19
DK2187741T3 (da) 2012-04-16
SI2450057T1 (sl) 2017-01-31
CN101820758B (zh) 2013-03-06
DK2450057T3 (en) 2016-12-19
HRP20120350T1 (hr) 2012-05-31
TWI486357B (zh) 2015-06-01
HK1143537A1 (en) 2011-01-07
KR20100056488A (ko) 2010-05-27
CA2871864C (fr) 2016-05-17
AR119704A2 (es) 2022-01-05
CN103254267B (zh) 2016-03-16
US20120330050A1 (en) 2012-12-27
US8633243B2 (en) 2014-01-21
AU2008287388B2 (en) 2014-11-06
CY1118329T1 (el) 2017-06-28
KR101481764B1 (ko) 2015-01-13
US20090048204A1 (en) 2009-02-19
NZ583269A (en) 2012-03-30
EP2450057B1 (fr) 2016-09-28
TWI419899B (zh) 2013-12-21
SG10201504650VA (en) 2015-07-30
EP2187741B1 (fr) 2012-03-14
EA201070149A1 (ru) 2010-08-30
EP2450057A1 (fr) 2012-05-09
HRP20161503T1 (hr) 2017-01-13
ATE549035T1 (de) 2012-03-15
EP2187741A4 (fr) 2010-08-25
CL2008002417A1 (es) 2009-03-27
US8309601B2 (en) 2012-11-13
JP2010536754A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
ZA201001066B (en) Novel forms of CDDO methyl ester
PL3296284T3 (pl) Nieterapeutyczne zastosowanie estru hydroksymaślanowego
IL234285B (en) A process for the preparation of boronate ester compounds and their intermediates
EP2250185A4 (fr) Nouveaux dérivés de lupane
ZA201006252B (en) Preparation of lenalidomide
EP2282755A4 (fr) Inhibition de l'angiogenèse
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
EP2231687A4 (fr) Nouveaux dérivés d'acyle cyanopyrrolidines
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
GB0810219D0 (en) Masonary bracket
IL211052A0 (en) Synthesis of glatiramer acetate
HUE037655T2 (hu) Egy észteráz elõállítása
ZA201006228B (en) Combined use of cholestanol derivative
PL2278890T3 (pl) Kompozycje fitosteroli o zwiększonej dostępności biologicznej
GB201114396D0 (en) Location of basesation
EP2331490A4 (fr) Préparation de dibutoxyméthane
IL206021A0 (en) Crystalline form of azelastine
GB2460350B (en) Intermediates for the preparation of bile acids
PL384673A1 (pl) Zestaw podokładzinowych listew dekoracyjnych
GB0809256D0 (en) Hollow wall fixing
PL386302A1 (pl) Nowa pochodna izotiazolopirydyny
GB0811883D0 (en) Preparation of glycoside esters
GB0708898D0 (en) Preparation of glycoside esters
GB0821710D0 (en) Derivatives of dihydroindolone
TWM311768U (en) Improved structure of A-ladder